文献速递乳腺乳腺X线USMR

导管原位癌检测与管理的进展

Advancements in Detection and Management of Ductal Carcinoma in Situ.
PubMed 文献 · Radiographics · 2025-01-01

导管原位癌(DCIS)是一种非浸润性乳腺癌,具有组织学、影像学和临床表现的异质性,部分病变可进展为浸润性癌。随着钼靶筛查普及,DCIS检出率上升,过度诊断和过度治疗问题受到关注。放射科医生需了解钼靶、对比增强乳腺摄影、断层合成、超声和MRI等影像技术评估DCIS的优势与局限,以制定合适治疗方案。当前指南建议所有DCIS均接受手术、放疗和内分泌治疗,但低危DCIS主动监测的安全性正在试验中。影像组学和人工智能等新工具有初步阳性结果,但需进一步研究才能广泛用于临床。

要点

  • DCIS为基底膜内非浸润性病变,可进展为浸润性导管癌,但并非所有病变均进展。
  • 影像评估手段包括钼靶、对比增强乳腺摄影、断层合成、超声和MRI,需熟悉各 modality 优势与局限。
  • 当前指南建议所有DCIS行手术、放疗和内分泌治疗;低危DCIS主动监测的安全性正在试验中。

核心结论

  • DCIS是一种异质性非浸润性乳腺癌,影像学检查在检出和评估中起关键作用;当前指南建议所有病例接受手术、放疗和内分泌治疗,低危DCIS主动监测的安全性正在试验中;影像组学和人工智能等新工具初步结果积极,但需进一步研究才能广泛临床采用。

研究设计与样本

  • 综述,检索范围与纳入文献数原文未报告。

关键影像表现/征象

  • DCIS表现为局限于导管系统、基底膜未突破的肿瘤性上皮细胞,无邻近组织浸润。
  • DCIS进展为浸润性癌的机制尚未完全阐明,目前认为是浸润性乳腺癌的非必需前驱病变。
  • DCIS包括组织学、免疫组化、遗传学、影像学和临床特征各异的异质性病变群,自然病程不同,部分惰性,部分可发展为浸润性导管癌。

诊断标准与关键数值

  • 原文未报告DCIS的敏感度、特异度、AUC、阈值或分级标准的具体数值。

临床应用与阅片要点

  • 放射科医生应熟悉钼靶、对比增强乳腺摄影、断层合成、超声和MRI各自评估DCIS的优势与局限,以有效评估DCIS并制定合适治疗方案。

局限性

  • 原文指出DCIS进展为浸润性癌的机制尚未完全理解。
  • 原文指出影像组学、人工智能等新工具需进一步研究和发展才能广泛用于临床实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Ductal carcinoma in situ (DCIS) is a noninvasive breast cancer characterized by neoplastic epithelial cells confined to the ductal system by the basement membrane without invasion of adjacent tissue. Its progression to invasive carcinoma is not understood fully, and currently, DCIS is considered a nonobligatory precursor of invasive breast cancer. However, DCIS is challenging because it includes a heterogeneous group of lesions with varied histologic, immunohistochemical, genetic, radiologic, and clinical characteristics. This heterogeneity is reflected in its natural progression, with some lesions remaining indolent, whereas others may develop into invasive ductal carcinoma. As DCIS detection rates rise due to mammographic screening, concerns about overdiagnosis and overtreatment have emerged, which has lead to a greater focus on understanding the biologic characteristics of DCIS. Radiologists need to understand the various imaging techniques used to evaluate DCIS. These include mammography, contrast-enhanced mammography, tomosynthesis, US, and MRI. By familiarizing themselves with each modality's various strengths and limitations, radiologists can effectively assess DCIS and develop the appropriate treatment plan. Although current guidelines advise treating all cases of DCIS with surgery, radiation therapy, and hormonal therapy, ongoing trials are investigating the safety of active surveillance for women with low-risk DCIS. There is interest in improving the risk stratification of DCIS lesions, and new advanced tools, such as radiomics, artificial intelligence, and other emerging techniques, are showing positive initial results and have the potential to become valuable solutions in the future. However, further studies and development still are needed before they can be widely adopted in clinical practice. Published under a CC BY 4.0 license See the invited commentary by Chikarmane in this issue.

来源:Radiographics,查看原文。版权归原作者所有。

引用

  1. Tucunduva TCM, Zanetta VC, Chala LF, et al. Advancements in Detection and Management of Ductal Carcinoma in Situ. Radiographics. 2025. PMID: 40773373. doi:10.1148/rg.240174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。